Leukemia and lymphoma are hematologic neoplasms that affect members of all age groups. Each year, over 140,000 people in the US are diagnosed with a hematologic malignancy of some kind. With constant advancement of treatment options, the importance of accurate diagnosis and detection of lymphomas and leukemias becomes more and more relevant to the survival of the patient, and immunohistochemistry has served as a key auxiliary test in determining these diagnoses. This presentation covers many of the basic science, facts, and statistics of hematologic malignancies, as well as the utility of immunohistochemical testing with markers such as CD20, PAX-5, CD61, CD71, Cyclin D1, and SOX-11 in the accurate diagnosis and survival rates of lymphoma and leukemia.
What Will You Learn?
Who Should Attend?
OEM Sales Manager
Jeff Gordon is the OEM Sales Manager for Tissue Diagnostics. He has a Bachelor of Science in Microbiology from the University of Arkansas. In his over 17 years in the diagnostic Immunohistochemistry industry, he has served as a technical consultant managing territories covering most of the United States and Canada, as International Sales Manager, and as the Director of Sales and Marketing for Cell Marque before transitioning to OEM Sales Manager. His roles have involved sales, marketing, customer care/complaint handling, and product development. He has given over 60 IHC-related workshops and webinars at a local, state, national, and international level.
Research and disease areas
Clinical testing and diagnostics manufacturing
Presented:April 27, 2018